Jennifer A. Rothman
Elite in Pyruvate Kinase Deficiency

Dr. Jennifer A. Rothman

Pediatrics
2301 Erwin Rd, 
Durham, NC 
On Staff At
Offers Telehealth
22 Years of Experience
Elite in Pyruvate Kinase Deficiency
2301 Erwin Rd, 
Durham, NC 
OverviewInsuranceLocationsClinical Research

Overview

I treat children with cancer and blood disorders, such as anemia and sickle cell disease. When families come in, there is understandably a huge amount of anxiety. I try to spend a lot of time with them and discuss what we know, what we need to find out, and how we plan to care for their children. My goal is to make it the least scary as possible for both the children and the parents/caregivers while providing the best care. Even in the setting of severe illness, interacting with children is uplifting and extremely rewarding. Children truly demonstrate the resilience of the human spirit. What I love most about my job is having relationships with children and seeing them grow; it is a wonderful experience.

Dr. Rothman is rated as an Elite provider by MediFind in the treatment of Pyruvate Kinase Deficiency. Her top areas of expertise are Pyruvate Kinase Deficiency, Anemia, Hemolytic Anemia, Congenital Hemolytic Anemia, and Splenectomy.

Her clinical research consists of co-authoring 43 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 7 articles and participated in 1 clinical trial in the study of Pyruvate Kinase Deficiency.

Graduate Institution
University Of Medicine And Dentistry Of New Jersey-Robert Wood Johnson Medical School, 2003
Specialties
Pediatrics
Licenses
Pediatric Hematology-Oncology in NC
Board Certifications
American Board Of Pediatrics, Pediatric Hematology-Oncology
Fellowships
Pediatric Hematology and Oncology, Children's Hospital of Philadelphia (Pennsylvania)
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Ambetter
  • EPO
  • HMO
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Piedmont
  • HMO
  • POS
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
TeamCare
  • OTHER COMMERCIAL
Trillium
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Duke Children's Health Center Hematology/Oncology Clinic
2301 Erwin Rd, Durham, NC 27710

Additional Areas of Focus

Dr. Rothman has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase III Study of Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia in Children
A Phase III Study of Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia in Children
Enrollment Status: Completed
Publish Date: July 29, 2025
Intervention Type: Drug
Study Drugs: Eltrombopag, Steroids, IVIg, Rho(D) Immune Globulin
Study Phase: Phase 3
A Phase 2,Multicenter,Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab,With or Without Hydroxyurea/Hydroxycarbamide,in Sequential,Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso-Occlusive Crisis
A Phase 2,Multicenter,Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab,With or Without Hydroxyurea/Hydroxycarbamide,in Sequential,Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso-Occlusive Crisis
Enrollment Status: Completed
Publish Date: July 20, 2025
Intervention Type: Drug
Study Drug: Crizanlizumab
Study Phase: Phase 2
A Phase II, Open-label, Non-controlled, Intra-patient Dose-escalation Study to Characterize the Pharmacokinetics After Oral Administration of Eltrombopag in Pediatric Patients With Refractory, Relapsed or Treatment Naive Severe Aplastic Anemia or Recurrent Aplastic Anemia
A Phase II, Open-label, Non-controlled, Intra-patient Dose-escalation Study to Characterize the Pharmacokinetics After Oral Administration of Eltrombopag in Pediatric Patients With Refractory, Relapsed or Treatment Naive Severe Aplastic Anemia or Recurrent Aplastic Anemia
Enrollment Status: Completed
Publish Date: March 04, 2025
Intervention Type: Drug
Study Drugs: Eltrombopag, Anti-Thymocyte Globulin, Cyclosporine
Study Phase: Phase 2
Pyruvate Kinase Deficiency (PKD) Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Enrollment Status: Completed
Publish Date: May 22, 2020
View 3 Less Clinical Trials

43 Total Publications

Working toward international consensus defining pediatric "refractory ITP".
Working toward international consensus defining pediatric "refractory ITP".
Journal: Blood advances
Published: December 17, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rothman's expertise for a condition
ConditionClose
View All 17 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile